Hendrickson recounts Perrigo's strategies to right the ship after a hole in earnings opened from investing in a European consumer health business and operating API and dietary supplement divisions and as pricing pressures on generic drugs took some wind out of its revenue sails.
Perrigo Co. PLC CEO John Hendrickson says his successor will take the helm of a firm "positioned in exactly the right place" to grow after trimming businesses competing in markets outside its core areas of consumer health products and Rx generics.
Uwe Rohrhoff's plans for Perrigo's Rx generics business after he starts as president and CEO on Jan. 15 (see sidebar...
Ensitrelvir, Shionogi's treatment for COVID-19, is among the latest products that have been filed for review by the European Medicines Agency for potential EU marketing approval.
AbbVie didn’t get everything it sought from a citizen petition but may still have the upper hand over smaller rivals after FDA gives makers of animal-derived thyroid medications a year to seek approval. If the agency removes compounded products, it could face more pricing pushback.
The findings are consistent with some other research and likely are due to obesity patients becoming more connected to needed health care services.
